Commentary Open Access
Volume 3 | Issue 4 | DOI: https://doi.org/10.33696/diabetes.3.048

The Emerging Target Protein Tyrosine Phosphatase 1B (PTP1B) for Type 2 Diabetes Mellitus Management

  • 1LAQV, REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
  • 2Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, 1649-003 Lisboa, Portugal
+ Affiliations - Affiliations

Corresponding Author

Marisa Freitas, marisafreitas@ff.up.pt
Eduarda Fernandes, egracas@ff.up.pt

Received Date: September 09, 2021

Accepted Date: October 19, 2021


Type 2 diabetes mellitus is one of the greatest health burdens of our society. Despite the extensive options of current drug treatments, novel therapies are under development to manage this chronic disorder and its subsequent complications. The inhibition of the enzyme protein tyrosine phosphatase 1B (PTP1B) is a promising therapeutic intervention in diabetes and obesity. However, finding selective PTP1B inhibitors remains a challenge. The pyrazole scaffold is considered of high pharmaceutical interest due to the high range of pharmacological activities. Nonetheless, the study of their effect against PTP1B activity have not yet been fully explored, opening a new field of research to find a new potential approach for type 2 diabetes mellitus management. This commentary presents and discusses PTP1B as an emerging target for type 2 diabetes mellitus management.


Protein tyrosine phosphatase 1B, Pyrazoles, Insulin resistance, Type 2 diabetes, Obesity

Author Information X